Do analysts prefer BPTH or MTEX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BPTH or MTEX?

Mannatech has higher revenue and earnings than Bio-Path. Mannatech is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Mannatech $108.04M 0.08 -$15.21M -$6.71 N/A

Is BPTH or MTEX more profitable?

Bio-Path has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Mannatech's return on equity of -2,383.34% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Mannatech -11.97% -2,383.34% -40.24%

Does the media favor BPTH or MTEX?

In the previous week, Mannatech had 3 more articles in the media than Bio-Path. MarketBeat recorded 4 mentions for Mannatech and 1 mentions for Bio-Path. Mannatech's average media sentiment score of 0.64 beat Bio-Path's score of 0.00 indicating that Mannatech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Path 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mannatech 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, LIAN or BPTH?

LianBio is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is LIAN or BPTH more profitable?

LianBio's return on equity of -33.17% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Bio-Path N/A -2,842.40% -337.48%

Do analysts recommend TRAW or BPTH?

Traws Pharma presently has a consensus target price of $1.00, indicating a potential upside of 104.88%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Traws Pharma is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is TRAW or BPTH more profitable?

Traws Pharma's return on equity of -913.18% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% Bio-Path N/A -2,842.40% -337.48%

Do analysts recommend BPTH or APRE?

Aprea Therapeutics has a consensus price target of $4.07, suggesting a potential upside of 543.46%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better valuation & earnings, BPTH or APRE?

Aprea Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Aprea Therapeutics N/A N/A -$12.60M -$1.54 N/A

Is BPTH or APRE more profitable?

Bio-Path has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Aprea Therapeutics -4,405.59% -61.03% -50.24%

Do analysts rate MTVA or BPTH?

MetaVia presently has a consensus target price of $20.00, suggesting a potential upside of 1,251.35%. Given MetaVia's stronger consensus rating and higher probable upside, analysts plainly believe MetaVia is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, MTVA or BPTH?

MetaVia is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$5.19 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is MTVA or BPTH more profitable?

MetaVia's return on equity of -172.92% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Bio-Path N/A -2,842.40% -337.48%

Bio-Path (BPTH) Competitors

$0.04 +0.00 (+5.26%)

As of 07/24/2026 01:58 PM Eastern

Compare

BPTH vs. MTEX, LIAN, TRAW, APRE, and MTVA

Should you buy Bio-Path stock or one of its competitors? MarketBeat compares Bio-Path with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Path include Mannatech (MTEX), LianBio (LIAN), Traws Pharma (TRAW), Aprea Therapeutics (APRE), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry.

How does Bio-Path compare to Mannatech?

Bio-Path (NASDAQ:BPTH) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Bio-Path has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Mannatech's return on equity of -2,383.34% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Mannatech	-11.97%	-2,383.34%	-40.24%

Bio-Path has a beta of -0.51, suggesting that its share price is 151% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 47.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Mannatech had 3 more articles in the media than Bio-Path. MarketBeat recorded 4 mentions for Mannatech and 1 mentions for Bio-Path. Mannatech's average media sentiment score of 0.64 beat Bio-Path's score of 0.00 indicating that Mannatech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Path	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mannatech	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mannatech has higher revenue and earnings than Bio-Path. Mannatech is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mannatech beats Bio-Path on 10 of the 13 factors compared between the two stocks.

How does Bio-Path compare to LianBio?

LianBio (NASDAQ:LIAN) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, Bio-Path had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for Bio-Path and 0 mentions for LianBio. LianBio's average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Bio-Path	Neutral

74.8% of LianBio shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, suggesting that its stock price is 151% less volatile than the broader market.

LianBio is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

LianBio's return on equity of -33.17% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Bio-Path	N/A	-2,842.40%	-337.48%

Summary

LianBio beats Bio-Path on 6 of the 9 factors compared between the two stocks.

How does Bio-Path compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Traws Pharma has higher revenue and earnings than Bio-Path. Traws Pharma is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	2.65	$9.17M	-$1.69	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Traws Pharma presently has a consensus target price of $1.00, indicating a potential upside of 104.88%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Traws Pharma is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Traws Pharma's return on equity of -913.18% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Bio-Path	N/A	-2,842.40%	-337.48%

Traws Pharma has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market.

In the previous week, Traws Pharma and Traws Pharma both had 1 articles in the media. Traws Pharma's average media sentiment score of 1.89 beat Bio-Path's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Traws Pharma	Very Positive
Bio-Path	Neutral

Summary

Traws Pharma beats Bio-Path on 10 of the 12 factors compared between the two stocks.

How does Bio-Path compare to Aprea Therapeutics?

Bio-Path (NASDAQ:BPTH) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Bio-Path has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Aprea Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aprea Therapeutics has a consensus price target of $4.07, suggesting a potential upside of 543.46%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Bio-Path and Bio-Path both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 1.87 beat Bio-Path's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Bio-Path	Neutral
Aprea Therapeutics	Very Positive

Bio-Path has a beta of -0.51, meaning that its share price is 151% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Summary

Aprea Therapeutics beats Bio-Path on 10 of the 13 factors compared between the two stocks.

How does Bio-Path compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 0.6% of MetaVia shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, MetaVia had 1 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for MetaVia and 1 mentions for Bio-Path. MetaVia's average media sentiment score of 0.44 beat Bio-Path's score of 0.00 indicating that MetaVia is being referred to more favorably in the media.

Company	Overall Sentiment
MetaVia	Neutral
Bio-Path	Neutral

MetaVia has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, suggesting that its share price is 151% less volatile than the broader market.

MetaVia presently has a consensus target price of $20.00, suggesting a potential upside of 1,251.35%. Given MetaVia's stronger consensus rating and higher probable upside, analysts plainly believe MetaVia is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

MetaVia's return on equity of -172.92% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Bio-Path	N/A	-2,842.40%	-337.48%

MetaVia is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Summary

MetaVia beats Bio-Path on 9 of the 13 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTH vs. The Competition

Export

Metric	Bio-Path	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.91M	$975.85M	$6.87B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-0.04	1.53	27.14	23.64
Price / Sales	N/A	104.46	517.08	89.45
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	0.06	8.47	10.28	6.07
Net Income	-$16.08M	-$2.70M	$3.60B	$331.99M
7 Day Performance	N/A	-2.29%	-1.27%	-0.63%
1 Month Performance	N/A	-3.97%	-0.37%	-2.00%
1 Year Performance	N/A	27.39%	18.30%	13.62%

Bio-Path Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTH Bio-Path	N/A	$0.04 +5.3%	N/A	-74.2%	$1.91M	N/A	N/A	10	News Coverage Gap Up
MTEX Mannatech	1.1076 of 5 stars	$4.61 +0.7%	N/A	-44.5%	$8.90M	$108.04M	N/A	250	News Coverage Positive News Gap Down
LIAN LianBio	N/A	$0.08 flat	N/A	+3.7%	$8.65M	N/A	N/A	110
TRAW Traws Pharma	3.5435 of 5 stars	$0.57 -6.0%	$1.00 +75.4%	-70.1%	$8.64M	$2.79M	N/A	17	Positive News
APRE Aprea Therapeutics	4.1421 of 5 stars	$0.69 +5.8%	$4.07 +489.4%	-67.3%	$8.54M	N/A	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Path (BPTH) Competitors